Katie Kosko | Authors


Machines and Patient Power Move Biomarker Discoveries Forward

March 27, 2021

The biggest unanswered question in biomarker development for cancer is how to determine which patients will respond to targeted therapy or immunotherapy. Investigators around the world are trying to answer this through clinical trials and data mining, in addition to finding new tools to add to the mix.

Breast Cancer Surgery Choice May Have Long-Term Impact on QoL, Study Finds

January 03, 2019

Findings of a recent study suggest surgical choices in women with breast cancer may have long-term impacts on their quality of life. Investigators found that younger patients with breast cancer who underwent lumpectomy had better QOL outcomes than patients who had a mastectomy.

New Approach Helps Direct Best Maintenance Therapy Choice for Patients With Ovarian Cancer

March 26, 2018

The United States Food and Drug Administration approved several maintenance therapies over the last few years for the management of platinum-sensitive recurrent ovarian cancer. Bevacizumab (Avastin), TKIs, or PARP inhibitors were among the treatments used in the clinical trials leading to these approvals.

Early Biomarkers Found for Patients Requiring Dose Reduction With Niraparib in Ovarian Cancer

March 25, 2018

In an analysis of the phase III ENGOT-OV16/NOVA study, baseline body weight and platelet counts served as early biomarkers for patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who would require dose modifications to their treatment with niraparib (Zejula).

Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer

March 25, 2018

According to study findings presented during the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers held in New Orleans March 24-27, clinical benefit has been found for women with recurrent ovarian cancer when using immune checkpoint inhibitors, but there was a higher rate of adverse events (AEs) than previously reported in other tumor types.